Johnston AJ, Murphy KT, Jenkinson L, et al. Targeting of Fn14 Prevents Cancer-Induced Cachexia and Prolongs Survival. Cell. 2015;162(6):1365-78. doi:10.1016/j.cell.2015.08.031
Paez G, Jänne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304(5676):1497-500. doi:10.1126/science.1099314
Akbay EA, Koyama S, Carretero J, et al. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov. 2013;3(12):1355-63. doi:10.1158/2159-8290.CD-13-0310
Rosenberg MW, Kato CM, Carson KMP, et al. Circumferential or sectored beam arrangements for stereotactic body radiation therapy (SBRT) of primary lung tumors: effect on target and normal-structure dose-volume metrics. Med Dosim. 2013;38(4):407-12. doi:10.1016/j.meddos.2013.05.002
Hagerstrand D, Tong A, Schumacher SE, et al. Systematic interrogation of 3q26 identifies TLOC1 and SKIL as cancer drivers. Cancer Discov. 2013;3(9):1044-57. doi:10.1158/2159-8290.CD-12-0592
Liao RG, Jung J, Tchaicha J, et al. Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell carcinoma. Cancer Res. 2013;73(16):5195-205. doi:10.1158/0008-5472.CAN-12-3950
Lawrence MS, Stojanov P, Polak P, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013;499(7457):214-218. doi:10.1038/nature12213
Watanabe H, Meyerson M. Hopping between differentiation states in lung adenocarcinoma. Cancer Cell. 2013;23(6):707-9. doi:10.1016/j.ccr.2013.05.013
Imielinski M, Berger AH, Hammerman PS, et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell. 2012;150(6):1107-20. doi:10.1016/j.cell.2012.08.029
Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature. 2012;489(7417):519-25. doi:10.1038/nature11404